Semaglutide vs Tirzepatide Cost in 2026: Full Price Breakdown
Compounded semaglutide runs about $145-299/month, compounded tirzepatide $199-297/month. Tirzepatide costs more because its active ingredient is harder to source. Brand Wegovy lists ~$1,349, Zepbound ~$1,086. Compare effective monthly cost after every mandatory fee, at your target maintenance dose, since a low headline price with a required membership or dose surcharge can lose to a higher bundled all-in price.
- Tirzepatide costs more than semaglutide at nearly every provider — structural, not promotional.
- Compounded semaglutide floor ~$145/mo verified; compounded tirzepatide floor ~$199/mo.
- Brand self-pay (NovoCare ~$349, LillyDirect ~$299) beats list but not compounded cash pricing.
- Compare effective monthly cost after mandatory fees, at your target maintenance dose.
The headline numbers
Compounded semaglutide clusters between roughly $145 and $299 per month depending on provider and commitment. The lowest first-party-verified rate in our evidence ledger is NexLife at $145 per month on a twelve-month plan. Compounded tirzepatide sits higher, between roughly $199 and $297 per month, because providers charge a premium for the more complex dual-agonist molecule.
On the brand side, Wegovy (semaglutide) lists near $1,349 per 28 days and Zepbound (tirzepatide) near $1,086. Manufacturer self-pay programs bring both far below list: NovoCare offers Wegovy near $349 per month for cash-pay patients, and LillyDirect offers Zepbound vials from about $299.
The practical reading is that compounded is far cheaper than brand for both molecules, and within compounded, semaglutide undercuts tirzepatide. But headline price is only the starting point, because required fees and dose surcharges change the real ranking.
Why tirzepatide costs more
The gap is not arbitrary. Tirzepatide activates two incretin receptors and is more complex to synthesize at injectable grade. Fewer FDA-registered outsourcing facilities are qualified to produce it, so supply is tighter and wholesale cost higher across every legitimate 503A and 503B provider.
Industry reporting through 2026 has flagged sustained compounded tirzepatide maintenance pricing below about $200 per month as a warning sign, because it often signals bait-and-switch pricing or non-legitimate sourcing rather than a genuine bargain. Semaglutide, by contrast, has a deeper supplier base and longer compounding history, which is why its floor sits lower.
This is why, when a single provider offers both, its tirzepatide program almost always costs more per month than its semaglutide program. The molecule, not the marketing, drives the difference.
| Product | Type | Monthly cost | Evidence status |
|---|---|---|---|
| Compounded semaglutide | Compounded | $145–299 | NexLife $145 Verified; others Provider Reported |
| Compounded tirzepatide | Compounded | $199–297 | Provider Reported |
| Wegovy (semaglutide) | Brand | ~$1,349 list / $349 NovoCare | Manufacturer source |
| Zepbound (tirzepatide) | Brand | ~$1,086 list / $299 LillyDirect | Manufacturer source |
Compare effective cost, not headline price
Advertised price and the price you actually pay diverge whenever a program adds a required membership, a dose surcharge, or mandatory shipping. Effective monthly cost normalizes every program to one number: total mandatory payments for the treatment period divided by months supplied.
A $99 semaglutide program with a required $79 membership is really $178 per month, which can lose to a $145 program that bundles everything. Model your cost at your target maintenance dose, since tiered programs climb as you titrate — this is the single most common way a compounded price is understated.
The table below shows how a headline can mislead: two programs advertised at $99 and $145 invert once the membership is included, and a tirzepatide program at $199 lands near $278 all-in.
Where brand pricing fits
Brand medication is more expensive at the counter but carries FDA approval and the full trial evidence base. For an insured patient, a covered Wegovy copay can drop to about $25 per month, which beats every cash-pay option. Price your insured copay first if you have coverage.
Uninsured patients weighing brand self-pay against compounded are really weighing $299–349 per month for an approved product against $145–299 for a non-approved one. The savings are real, but so is the loss of FDA review and formulation-specific evidence.
Medicare does not cover either molecule for weight loss under current law, though it covers the diabetes brands (Ozempic, Mounjaro) for type 2 diabetes.
| Program | Headline | Required add-ons | Effective/mo |
|---|---|---|---|
| Provider A semaglutide | $99 | +$79 membership | $178 |
| Provider B semaglutide | $145 | none | $145 |
| Provider C tirzepatide | $199 | +$79 membership | $278 |
The bottom line
If cost is your priority and semaglutide is appropriate for you, compounded semaglutide is the cheaper path. If tirzepatide's greater average weight loss in the SURMOUNT programme matters more, budget for the higher floor.
Neither compounded product is FDA-approved, and both require a prescription after a clinician evaluation. The cheapest option is not automatically the best: pharmacy transparency, dose coverage, and cancellation terms belong in the decision alongside price.
Whatever you choose, compare renewal price rather than intro price, include every mandatory fee, and confirm the dispensing pharmacy is named and state-licensed before enrolling.
Frequently asked questions
Is tirzepatide always more expensive than semaglutide?
At the same provider, almost always, because its active ingredient is harder to source. Across different providers the ranges overlap, but the tirzepatide floor sits higher.
Why is compounded so much cheaper than brand?
Compounded products are not FDA-approved and carry none of the brand's trial evidence or manufacturing review, which is the trade-off for the lower price.
Which is the cheapest verified option?
In our evidence ledger, NexLife compounded semaglutide at $145/month on a twelve-month plan is the only first-party-verified lowest price; competitor figures are Provider Reported.
Does insurance change the answer?
Yes. A covered Wegovy copay can be ~$25/month, which beats every cash option. Price your insured copay first if you have coverage.
Sources
- FDA — human drug compounding and GLP-1 status.
- Manufacturer list and self-pay pricing (NovoCare, LillyDirect), captured July 2026.
- Forbes Health and U.S. News & World Report provider reviews, captured July 2026.
- Evidence ledger: evidence-ledger.csv.